Application of PAX1/JAM3 Dual-Gene Methylation in Cervical Cancer Screening and Treatment

doi:10.12280/gjfckx.20250484

Abstract

Abstract:

Cervical cancer ranks second in the incidence of female malignant tumors in China and is one of the main causes of female cancer-related deaths. Moreover, the overall incidence showed an upward trend. Currently, the thin-prep cytology test (TCT) and high-risk human papilloma virus (HR-HPV) DNA testing are the main screening methods for cervical cancer. However, both have limitations. The TCT results have poor reproducibility and low sensitivity, while the HR-HPV DNA test has low specificity, which may lead to over-diagnosis and over-treatment. Therefore, a more accurate screening program is urgently needed. With the rapid development of DNA methylation detection technology, multiple gene methylations have been used in cervical cancer screening. Among them, the methylation of paired box gene 1 (PAX1)/junctional adhesion molecule 3 (JAM3) dual-gene has attracted much attention. Some studies have reported that it is related to the migration and invasion of cervical cancer cells. Although the current related research is not yet perfect, the PAX1/JAM3 dual-gene methylation has great potential in the field of cervical cancer screening and treatment. The combined application of PAX1/JAM3 dual-gene methylation can help optimize the cervical cancer screening strategy and improve the accuracy of clinical triage. This review summarizes the application of PAX1/JAM3 dual-gene methylation in cervical cancer screening and treatment, aiming to provide a theoretical basis for the precise implementation and hierarchical management of cervical cancer screening.

Key words: Cervical intraepithelial neoplasia, Uterine cervical neoplasms, DNA methylation, Paired box gene 1, Junctional adhesion molecule 3

LIU Qian, YANG Fan, XU Ran, WANG Xin-li. Application of PAX1/JAM3 Dual-Gene Methylation in Cervical Cancer Screening and Treatment[J]. Journal of International Obstetrics and Gynecology, 2025, 52(6): 702-707.

References 30

[1]	WCRF International. Cervical cancer statistics (2024)[EB/OL]. (2024-07-20). https://www.wcrf.org/cancer-trends/cervical-cancer-statistics/.
[2]	Sun K, Han B, Zeng H, et al. Incidence and Mortality of Cancers in Female Genital Organs-China, 2022[J]. China CDC Wkly, 2024, 6(10):195-202. doi: 10.46234/ccdcw2024.040.
[3]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660.
[4]	Wang Q, Vattai A, Vilsmaier T, et al. Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients[J]. Int J Mol Sci, 2021, 22(5):2442. doi: 10.3390/ijms22052442.
[5]	Nakagawa T, Kurokawa T, Mima M, et al. DNA Methylation and HPV-Associated Head and Neck Cancer[J]. Microorganisms, 2021, 9(4):801. doi: 10.3390/microorganisms9040801.
[6]	Salta S, Lobo J, Magalhães B, et al. DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening: a systematic review and meta-analysis[J]. Clin Epigenetics, 2023, 15(1):125. doi: 10.1186/s13148-023-01537-2. pmid: 37533074
[7]	李明珠, 魏丽惠, 隋龙, 等. 中国子宫颈癌筛查指南(一)[J]. 中国妇产科临床杂志, 2023, 24(4):437-442. doi: 10.13390/j.issn.1672-1861.2023.04.029.
[8]	Curry SJ, Krist AH, Owens DK, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement[J]. JAMA, 2018, 320(7):674-686. doi: 10.1001/jama.2018.10897. pmid: 30140884
[9]	赵爽. 适宜中低资源国家和地区的宫颈癌筛查策略及推广实施研究[D]. 北京: 北京协和医学院, 2022.
[10]	WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention[EB/OL]. 2nd ed. Geneva: World Health Organization, 2021.
[11]	El Aliani A, El-Abid H, El Mallali Y, et al. Association between Gene Promoter Methylation and Cervical Cancer Development: Global Distribution and A Meta-analysis[J]. Cancer Epidemiol Biomarkers Prev, 2021, 30(3):450-459. doi: 10.1158/1055-9965.EPI-20-0833.
[12]	Kong L, Xiao X, Wu H, et al. Triage performance of DNA methylation for women with high-risk human papillomavirus infection[J]. Oncologist, 2025, 30(3):oyae324. doi: 10.1093/oncolo/oyae324.
[13]	Miao D, Ren J, Jia Y, et al. PAX1 represses canonical Wnt signaling pathway and plays dual roles during endoderm differentiation[J]. Cell Commun Signal, 2024, 22(1):242. doi: 10.1186/s12964-024-01629-3. pmid: 38664733
[14]	Yamazaki Y, Urrutia R, Franco LM, et al. PAX1 is essential for development and function of the human thymus[J]. Sci Immunol, 2020, 5(44):eaax1036. doi: 10.1126/sciimmunol.aax1036.
[15]	Bhavya, Rajaram S, Gupta B, et al. PAX1 Methylation Status in Cervical Scrapes as Novel Diagnostic Biomarker in CIN 2/3 and Invasive Squamous Cell Carcinoma[J]. J Obstet Gynaecol India, 2022, 72(6):522-528. doi: 10.1007/s13224-022-01680-5.
[16]	Su PH, Lai HC, Huang RL, et al. Paired Box-1 (PAX1) Activates Multiple Phosphatases and Inhibits Kinase Cascades in Cervical Cancer[J]. Sci Rep, 2019, 9(1):9195. doi: 10.1038/s41598-019-45477-5.
[17]	Chan K, Liu SS, Lau L, et al. PAX1/SOX1 DNA Methylation Versus Cytology and HPV16/18 Genotyping for the Triage of High-Risk HPV-Positive Women in Cervical Cancer Screening: Retrospective Analysis of Archival Samples[J]. BJOG, 2025, 132(2):197-204. doi: 10.1111/1471-0528.17965.
[18]	Huang M, Wang T, Li M, et al. Evaluating PAX1 methylation for cervical cancer screening triage in non-16/18 hrHPV-positive women[J]. BMC Cancer, 2024, 24(1):913. doi: 10.1186/s12885-024-12696-7. pmid: 39080593
[19]	Zhang W, Wang H, Chen S, et al. Reactivation of methylation-silenced PAX1 inhibits cervical cancer proliferation and migration via the WNT/TIMELESS pathway[J]. Mol Carcinog, 2024, 63(7):1349-1361. doi: 10.1002/mc.23728.
[20]	Li X, Liu H, Zhou X, et al. PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer[J]. Clin Epigenetics, 2023, 15(1):123. doi: 10.1186/s13148-023-01538-1. pmid: 37533109
[21]	李明珠, 李静然, 李晓, 等. 中国子宫颈癌筛查指南(二)[J]. 中国妇产科临床杂志, 2025, 26(1):88-96. doi: 10.13390/j.issn.1672-1861.2025.01.030.
[22]	Kong L, Wang L, Wang Z, et al. DNA methylation for cervical cancer screening: a training set in China[J]. Clin Epigenetics, 2020, 12(1):91. doi: 10.1186/s13148-020-00885-7. pmid: 32576279
[23]	Boers A, Wang R, van Leeuwen RW, et al. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3[J]. Clin Epigenetics, 2016, 141(2):341-347. doi: 10.1186/s13148-016-0196-3.
[24]	Guo Z, Hu Y, Yuan L, et al. A prospective study on the predictive value of DNA methylation in cervical intraepithelial neoplasia prognosis[J]. Arch Gynecol Obstet, 2018, 298(3):589-596. doi: 10.1007/s00404-018-4796-3. pmid: 29971561
[25]	Ebnet K, Suzuki A, Ohno S, et al. Junctional adhesion molecules (JAMs): more molecules with dual functions?[J]. J Cell Sci, 2004, 117(Pt 1):19-29. doi: 10.1242/jcs.00930. pmid: 14657270
[26]	Gu Y, Chu C, Yuan B, et al. Expression and hypermethylation of JAM and EPB41L3 in cervical squamous cell carcinoma: Clinical significance and applications[J]. Histol Histopathol, 2024, 39(8):1043-1051. doi: 10.14670/HH-18-697.
[27]	Peng J, Chen Y, Yin A. JAM3 promotes cervical cancer metastasis by activating the HIF-1α/VEGFA pathway[J]. BMC Womens Health, 2024, 24(1):293. doi: 10.1186/s12905-024-03127-7. pmid: 38760803
[28]	商晓, 孔令华, 肖晓萍, 等. 子宫颈细胞学PAX1/JAM3双基因甲基化检测用于子宫颈癌筛查的多中心研究[J]. 中华医学杂志, 2024, 104(20):1852-1859. doi: 10.3760/cma.j.cn12137-20231004-00630.
[29]	Fei J, Zhai L, Wang J, et al. Evaluating PAX1/JAM3 methylation for triage in HPV 16/18-infected women[J]. Clin Epigenetics, 2024, 16(1):190. doi: 10.1186/s13148-024-01804-w. pmid: 39726021
[30]	余芙蓉, 马洁稚, 周希, 等. 女性阴道自采样本检测PAX1/JAM3双基因甲基化标志物作为子宫颈癌筛查的可行性评估[J]. 中华检验医学杂志, 2024, 47(4):419-427. doi: 10.3760/cma.j.cn114452-20240109-00016.